Black patient representation in anti-cancer drug development.

Alexander B. Karol,Rodrigo Paredes,Yu Fujiwara,Anna Argulian,Himanshu Joshi,Matt D. Galsky
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e13680
IF: 45.3
2024-05-31
Journal of Clinical Oncology
Abstract:e13680 Background: Black patient enrollment in cancer clinical trials is critical to improving the generalizability of trial results and advancing an understanding of potential differences in drug efficacy and safety in underrepresented populations. Prior research indicated that in 2018, Black patients comprised ~2.5% of accruals to phase III trials in oncology (1). Here, we probed whether the representation of Black patients has increased in contemporary trials. Methods: We systematically searched the clinicaltrials.gov database to review racial demographics for phase III clinical trials. These trials evaluated systemic anti-cancer therapies in adult patients between October 28 th 2013, and October 28 th 2023. Studies were excluded if they did not include racial demographic information. The demographics of the trials and cancer subtypes were recorded. 19-year domestic cancer specific prevalence data was obtained from United States Cancer Statistics as a reference to evaluate the representation of Black patients in the included clinical trials. P-values were calculated with a chi-squared test. Results: 436 trials met criteria for review and 238 trials, enrolling 115,969 patients, met our inclusion criteria. Among these patients, 72,471 (62.5%) were White, 1,895 (1.6%) were Black, 31,996 (35.9%) were from another race. Systemic therapies explored included: immunotherapy (99 trials, 41.6%), targeted therapy (110 trials, 47.9%), chemotherapy (17 trials, 7.6%), and other therapies (7 trials, 2.9%). Black patients were underrepresented in phase 3 trials across the vast majority of tumor types (Table). Sub-group analysis revealed significantly increased Black clinical trial representation in trials beginning enrollment in 2019-2022 versus 2013-2018 (2.3% vs 1.8%, p=0.02). Conclusions: Adult Black patients are significantly under-represented (<2%) in modern oncology trials. However, there has been a significant increase in Black enrollment since 2019. Ongoing efforts are needed to ensure optimal representation of Black patients in oncology trials. 1. Tharakan, Cancer, 2021. [Table: see text]
oncology
What problem does this paper attempt to address?